RELMADA THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
RELMADA THERAPEUTICS, INC. (RLMD) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $902.90 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $902.90K, a 73.82% decline year-over-year.
- RELMADA THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $956.19K, a 73.24% decline year-over-year.
- RELMADA THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $3.61M, a 54.62% decline year-over-year.
- RELMADA THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $3.45M, a 52.19% decline year-over-year.
- RELMADA THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $13.91M, a 53.93% decline from fiscal 2024.
- RELMADA THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $30.18M, a 31.10% decline from fiscal 2023.
- RELMADA THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $43.81M, a 0.87% decline from fiscal 2022.
- RELMADA THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $44.19M.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $902.90K 10-Q · filed 2026-08-06 | $1.86M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $956.19K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $13.91M 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $3.61M 10-Q · filed 2025-11-13 | $7.06M derived: sum of 2 quarters · filed 2026-08-06 | $10.63M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $3.45M 10-Q · filed 2026-08-06 | $7.02M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $3.57M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $30.18M 10-K · filed 2026-03-19 | |||
| 2024-09-30 | $7.95M 10-Q · filed 2025-11-13 | $15.16M derived: sum of 2 quarters · filed 2025-11-13 | $23.46M derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $7.21M 10-Q · filed 2025-11-13 | $15.51M derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $8.30M 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $43.81M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $11.39M 10-Q · filed 2024-11-07 | $22.56M derived: sum of 2 quarters · filed 2024-11-07 | $33.92M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $11.17M 10-Q · filed 2024-11-07 | $22.52M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $11.35M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $44.19M 10-K · filed 2024-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |